Founded in 2011 by Drs. Neil Hayes, Chuck Perou and Myla Lai-Goldman, GeneCentric is dedicated to enabling precise and effective treatment options for cancer patients through personalized molecular diagnostic assays and targeted drug development. We leverage our proprietary Cancer Subtype Platform (CSP®) to change the taxonomy of cancer through an integrated analysis of tumor genomics. By capturing a comprehensive picture of DNA, RNA and copy number biomarkers, CSP® can identify cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions.
CSP®’s novel cancer subtypes can be applied to large existing databases to test upfront hypotheses, leading to safer, faster, and more cost-effective clinical trials with rational patient subsets and improved health outcomes. CSP® has broad therapeutic potential and can enable new drug development as well as repurposing and repositioning projects.
To view the business team click here.
To view the scientific founders click here.
To view the board of directors click here
- Hatteras Venture Partners
- Bristol-Myers Squibb
- LabCorp Ventures